New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer is advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have already tried at least two different chemotherapy treatments, including one with fluorouracil and one with gemcitabine, and your cancer got worse during or after that treatment.
- Your tumor must test positive for a protein called CLDN18.2 (Claudin 18.2).
- You are generally able to care for yourself and are up and about more than half the day (ECOG score 0 or 2).
- Your blood counts and organ function (like liver and kidneys) are within a range that is safe for the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.